Intellia Therapeutics (NASDAQ: NTLA) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.
This table compares Intellia Therapeutics and Alkermes’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
68.1% of Intellia Therapeutics shares are held by institutional investors. 12.8% of Intellia Therapeutics shares are held by insiders. Comparatively, 5.3% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Intellia Therapeutics and Alkermes, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Intellia Therapeutics presently has a consensus target price of $33.00, suggesting a potential upside of 14.54%. Alkermes has a consensus target price of $65.00, suggesting a potential upside of 5.69%. Given Intellia Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Intellia Therapeutics is more favorable than Alkermes.
Earnings & Valuation
This table compares Intellia Therapeutics and Alkermes’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Intellia Therapeutics||$16.48 million||63.09||-$31.63 million||($1.55)||-18.59|
|Alkermes||$903.37 million||10.48||-$157.94 million||($0.94)||-65.43|
Intellia Therapeutics has higher earnings, but lower revenue than Alkermes. Alkermes is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Intellia Therapeutics beats Alkermes on 8 of the 13 factors compared between the two stocks.
About Intellia Therapeutics
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company’s division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company’s subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company’s products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company’s product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.